260258-91-1

Basic information

• Product Name: 1-phenyl-5-(4-pyridinyl)-1H-Benzimidazole
• Synonyms: 1-phenyl-5-(4-pyridinyl)-1H-Benzimidazole
• CAS NO: 260258-91-1
• Molecular Weight: 271.321
• Mol File: 260258-91-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1-phenyl-5-(4-pyridinyl)-1H-Benzimidazole(CAS DataBase Reference)
• NIST Chemistry Reference: 1-phenyl-5-(4-pyridinyl)-1H-Benzimidazole(260258-91-1)
• EPA Substance Registry System: 1-phenyl-5-(4-pyridinyl)-1H-Benzimidazole(260258-91-1)

Safety Data

• Hazardous Substances Data: 260258-91-1(Hazardous Substances Data)

Usage

Type

Synthetic compound
Benzimidazole derivative

Potential properties

Anti-cancer
Anti-inflammatory

Mechanism of action

Inhibition of telomerase
Enzyme involved in immortalization of cancer cells
Implicated in aging process and age-related diseases

Research findings

Inhibition of telomerase activity in cancer cells
Potential target for cancer therapy

Anti-inflammatory effects

Reduction of inflammation in animal models
Suggesting potential use in treating inflammatory diseases

Future research

Further investigation needed to understand therapeutic potential
Elucidation of mechanism of action in cancer and inflammation

Upstream product

• 1120-87-2 4-bromopyridin 
• 221636-18-6 5-Bromo-1-phenyl-1H-benzoimidazole 
• 364-73-8 4-Bromo-1-fluoro-2-nitrobenzene 
• 16588-25-3 4-bromo-2-nitro-N-phenylaminobenzene 
• 68765-53-7 4-bromo-N¹-phenyl-1,2-benzenediamine 
• 62-53-3 aniline 
• 1692-15-5 4-pyridylboronic acid 

Downstream Products

• 260258-92-2 4-(1-phenyl-1H-benzoimidazol-5-yl)-1H-pyridin-2-one 

Relevant articles and documents

Design and synthesis of 1,5-diarylbenzimidazoles as inhibitors of the VEGF-receptor KDR

1,5-Diarylbenzimidazoles have been identified as potent inhibitors of KDR kinase activity. The series was developed with a goal of finding compounds with optimal drug-like properties. This communication describes structural modifications in the series that enhance solubility, lower protein binding, and provide compounds with excellent potency and pharmacokinetic profiles.

Tyrosine kinase inhibitors

The present invention relates to benzinidazole compounds which inhibit tyrosine kinase enzymes, compositions which contain tyrosine kinase inhibiting compounds and methods of using tyrosine kinase inhibitors to treat tyrosine kinase-dependent diseases/conditions such as angiogenenesis, cancer, atherosclerosis, diabetic retinopathy or autoimmune diseases, in mammals.